Welcome

 

The Ludwig Boltzmann Institute Applied Diagnostics (lbi:ad) is a translational research institution of the Ludwig Boltzmann Gesellschaft which is combining a team of transdisciplinary scientists, academic and industrial partners from several countries. It follows a new dual biomarker concept for tumor diagnosis. The focus of the institute lies on the development of non-invasive diagnostic methods combining molecular epigenetic and genetic signatures with molecular imaging biomarkers for PET and SPECT analysis. The combination of these two methods will allow for improved functional, spatial and temporal assessment of tumor load and molecular tumor characterization.

If you like to support our research, donations are very welcome. For bank details, please send a short request to office@lbiad.lbg.ac.at.

Thank you very much!

Recent News

New project funded


Together, Thomas L. Mindt and his cooperation-partners Wolfgang Kandioller (University of Vienna) and Berthold Nock (Demokritos, Athens) received a grant by the Austrian Science Fund for the new
New Podcast - Epigenetic Biomarkers in Cancer


This podcast with Professor Gerda Egger (Department of Pathology, Medical University of Vienna and Ludwig Boltzmann Institute Applied Diagnostics) provides an overview
LBG Meeting for Health Sciences


>>The call for abstracts for the upcoming LBG Meeting for Health Sciences is now open!<<
 

You are invited to submit your abstract on:

Cardiovascular research
Haematology
Medical Imaging Cluster Festival


The first MIC (Medical Imaging Cluster) Festival took place on the 14th of June 2018 at the Medical University of Vienna. Modern imaging techniques have major impact in today’s medicine.
Research Paper in Theranostics by Johannes Längle
"DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells"

A new study by scientists

Share This: